anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PCT No. PCT/NL95/00134 Sec. 371 Date Oct. 11, 1996 Sec. 102(e) Date Oct. 11, 1996 PCT Filed Apr. 11, 1995 PCT Pub. No. WO95/27903 PCT Pub. Date Oct. 19, 1995A procedure to measure apoptosis in physiology and pathology in order to support clinical diagnosis and monitor efficacies of drugs and therapies. In particular a method for detecting and/or optionally quantifying and/or optionally isolating apoptotic cells in a sample, comprising contacting the sample with a detectable reagent having high affinity for phosphatidyl serine; and qualitatively and/or optionally quantitatively detecting cells that have reacted with the detectable reagent having high affinity for phosphatidyl serine preferably intact cells, detection occurring before or after an optional step for isolating apoptotic cells from non-apoptotic cells, which isolation can occur due to the fact that apoptotic cells have been provided with a detectable reagent having high affinity for phosphatidyl serine, the reagent also being selectable in a manner known per se. A suitable reagent having high affinity for phosphatidyl serine is a polypeptide or protein classified as an annexin. A kit for carrying out such methods is provided.
1311902 Grafted keratinous substrates COLGATE-PALMOLIVE CO 26 May 1970 [29 May 1969 (3)] 25205/70 Heading C3G A keratinous substrate which has been subjected to chemical reduction to convert disulphide to mercaptan is treated with an oxidizing medium comprising (a) a peroxy initiator and (b) a monomer containing at least one group of formula Specified reducing agents are water-soluble salts of thioglycolic acid or thioglycerol, alkali metal bisulphites and trihydroxymethyl phosphine, the agents being used in aqueous solution or in water/organic solvent solution. The monomer and initiator may be applied in similar solutions, which may also comprise a water-soluble halide as promoter. Examples are given in which hair, which may have been bleached or permanently waved, is reduced with sodium bisulphite or ammonium thioglycolate and treated with an aqueous ethanolic solution containing cumene hydroperoxide and a monomer selected from methyl methacrylate, calcium acrylate, acrylonitrile, t-butyl acrylate, t-butyl acrylamide, hexafluoroisopropyl acrylate, allyl methacrylate, lauryl methacrylate, octadecyl methacrylate, 4,5-pentenyl methacrylate, 2-hydroxyethyl methacrylate, 3-hydroxypropyl methacrylate, acrylamide and methacrylamide. Other peroxy initiators used are dibutyl peroxide, t-butyl hydroperoxide, benzoyl peroxide, peracetic acid and hydrogen peroxide. Hair grafted with methacrylic acid is treated with hexadecyl pyridinium chloride and hair grafted with dimethylaminoethyl methacrylate is dyed. In other examples, hair reduced with ammonium thioglycolate is treated with an aqueous ethylene glycol monomethyl ether solution containing potassium persulphate and methyl methacrylate.
An inventory management system for wirelessly taking inventories of medical trays comprises an easily assemblable and disassemblable enclosure comprising interconnected electrically conductive walls to form a Faraday cage. The interior space defined by the walls is large enough to accept the trays. RFID readers are placed within the enclosure directed at the tray to excite and read the RFID tags disposed on the medical articles within the tray. The walls of the enclosure are flexible and one of the walls is rolled up and down to act as an opening to the interior space. A host computer stores the inventory of the tray and compares it against a previous inventory existence for resupply purposes. The host computer also detects expired and recalled medical articles in the tray. If a recalled article is detected, the host computer determines if a substitute article exists.
According to the National Medical Products Administration (NMPA) Guidance on Proton and Carbon Ion treatment system clinical evaluation and clinical trial, the objective performance criteria for the validity of medical device treatment for trial use should be at least 80%, with an expected target of 95% in which the validity is defined as: Complete Response (CR)+ Partial Response (PR)+ Stable Disease (SD), and the definition of tumor disease control rate in this clinical trial is basically identical. Therefore, the clinical trial does not have a control group, but using single-arm objective performance criteria, when evaluating ProBeam radiotherapy for tumor patients, the main validity evaluation index of tumor disease control rate whether reach the objective performance criteria (80%); the main safety evaluation index of CTCAE grade 3 toxic reaction ratio is lower than the acceptable value (5%), CTCAE grade 4 and 5 toxic reaction ratio is acceptable value (0%).
These participants self-select their exercise intensity with the goal of walking 30-60 minutes on most days of the week. They're instructed to choose the intensity that makes them feel the best. For safety reasons, they are instructed not to exceed 59% of their heart rate reserve. This is choice-based exercise intensity with a focus on positive affect.
BACKGROUND: Postoperative delirium is a common distressing symptom experienced following laparoscopic cholecystectomy. The study aimed to investigate the influence of a low preoperative Mini-Cog testing score and 2 different anesthesia methods: total intravenous anaesthesia (TIVA) versus sevoflurane, on postoperative delirium in elderly patients undergoing laparoscopic cholecystectomy.
METHODS: A total of 84 patients over 60 years old who underwent laparoscopic cholecystectomy between March 1and - October 1 2023 were included in the study. Patients with a Mini-Cog score of 0-2 were considered to have low and possibly impaired neurocognitive function. We invastigated the effects of preoperative Mini-Cog score and the two anesthesia methods used on the incidence of postoperative delirium.
RESULTS: The proportion of patients with low Mini-Cog score in the preoperative period was 17.9%. Sevoflurane and TIVA was used in 41 and 43 patients respectively. The incidence of postoperative delirium in patients with low preoperative Mini-Cog scores was 66.7% at postoperative 0 h and 33.3% at the 1st hours. Postoperative delirium was found to be statistically higher in patients with low Mini-cog scores than in those with negatively-screened for Mini-cog scores (p: 0.01-0.035). In patients using sevoflurane, the incidence of postoperative delirium was 26.8% and 24.4% at the 0 and 1st hours, respectively. This was found to be statistically higher than in patients receiving TIVA (p: 0.036 - 0.010).
CONCLUSION: Low Mini-Cog score was an indicator of a higher risk of early postoperative delirium. Sevoflurane is more likely to cause postoperative delirium than TIVA.
TRIAL REGISTRATION: The study was registered on ClinicalTrials.gov (Identifier: NCT06597812) .
Multimodal low-opioid protocol provided for induction of anesthesia with intravenous (iv) propofol administration using the dosage of 1.5-2 mg/kg at 40 mg in interval of 10-15 seconds, iv fentanyl dosage 1-1.5 μg/kg and iv pipecuronium bromide dosage of 0.1 mg/kg. Before intubation of the trachea, a lidocaine 1 mg / kg bolus was added intravenously, with the simultaneous establishment of a continuous infusion at a dose of 1.5-2 mg/kg/h. All patients were administered a bolus of ketamine (0.5 mg/kg) and were started continuous infusion dexmedetomidine at a dose 0.7 μg/kg/h. If indicated fentanyl was used as additional analgesic during surgery by bolus injection. Depth of anesthesia was monitored with bispectral index; the dosage of sevoflurane from 1,5vol% to 2,5vol% was titrated to maintain BIS values from 40 to 60.
At Visit 1, participants will complete questionnaires about demographics, asthma control (if asthmatic) and exercise habits. The participants will have baseline spirometry performed, and skin prick testing for allergies. Skin testing is important as it can influence the level of exhaled nitric oxide and hence we would like to adjust our results for the presence of allergies. Subsequently, volunteers will undergo sputum induction and then have peripheral blood drawn for microRNA analysis. MicroRNA's are single-stranded RNA molecules of about 21-23 nucleotides in length regulating gene expression. Patterns of MicroRNA expression have been linked to heart disease and cancer. Similar patterns have not been identified in exercise-induced asthma. In total, including time for questions and recovery, the time for Visit 1 will be approximately 3 hours.

At Visit 2, which will occur 24 hours to 7 days after Visit 1 in order to minimize risk of asthma exacerbation, the participants will again have baseline spirometry. Baseline exhaled nitric oxide will be performed. Eucapnic Voluntary hyperventilation testing will then be performed. They then will have a second exhaled nitric oxide quantification, will undergo sputum induction and then have peripheral blood drawn for microRNA analysis, all occurring after EVH testing. In total, including time for questions and recovery, the time for Visit 2 will be approximately 2 hours.
Two injections of Dupilumab will be administered at Week 0/Visit 3 as a loading dose. Subsequently one injection of Dupilumab will be given every 2 weeks ± 3 days at home by the patient. The doses of investigational product must be separated by ≥11 days to avoid an overdose.
A young boy presented with features of non-traumatic Subarachnoid hemorrhage (SAH) with hematemesis and melaena. He has had past history of prolonged bleeding following cut injury even requiring blood transfusion after circumcision. On examination, he was found confused, severely anemic, with presence of neck rigidity and painful swelling of right knee joint. But no positive family history was found. Non-contrast CT scan showed SAH. Cerebral angiography showed no aneurysm but knee joint had features of hemarthrosis. He was resuscitated and hemophilia was diagnosed on the basis of clinical suspicion of clotting factor assay. Specific treatment started in collaboration with Department of Hematology. This is a rare presentation of hemophilia as well as very uncommon cause of non-traumatic non-aneurysmal SAH.
Multisystem inflammatory syndrome in children is a post-infectious presentation SARS-CoV-2 associated with expansion of the T cell receptor Vβ21.3+ T-cell subgroup. Here we apply muti-single cell omics to compare the inflammatory process in children with acute respiratory COVID-19 and those presenting with non SARS-CoV-2 infections in children. Here we show that in Multi-Inflammatory Syndrome in Children (MIS-C), the natural killer cell and monocyte population demonstrate heightened CD95 (Fas) and Interleuking 18 receptor expression. Additionally, TCR Vβ21.3+ CD4+ T-cells exhibit skewed differentiation towards T helper 1, 17 and regulatory T cells, with increased expression of the co-stimulation receptors ICOS, CD28 and interleukin 18 receptor. We observe no functional evidence for NLRP3 inflammasome pathway overactivation, though MIS-C monocytes show elevated active caspase 8. This, coupled with raised IL18 mRNA expression in CD16- NK cells on single cell RNA sequencing analysis, suggests interleukin 18 and CD95 signalling may trigger activation of TCR Vβ21.3+ T-cells in MIS-C, driven by increased IL-18 production from activated monocytes and CD16- Natural Killer cells.
Patients will be vaccinated intranodally three times biweekly with mDC (5x 106 cells; n=7, arm A). DC will be loaded with major histocompatibility complex (MHC) class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA and loaded with keyhole limpet hemocyanin (KLH) as an immune control.
The present invention discloses a process for dimethylation of active methylene groups. Specifically, the invention discloses aprocess for preparing3-amino-2,2- dimethylpropanamide. Compounds produced by the present dimethylation process such as 3-amino-2,2-dimethylpropanamide can be used as intermediates in the route of synthesis of therapeutic, prophylactic or diagnostic agent, for example aliskiren or cryptophycin. Particularly, the invention relates to embodiments further extending to processesfor preparing pharmaceutical dosage form comprising said therapeutic, prophylactic or diagnostic agents. More specifically, the invention relates to the use of compounds produced by the present dimethylation process for the manufacture of therapeutic, prophylactic or diagnostic agents or for the manufacture of pharmaceutical dosage forms comprising said therapeutic, prophylactic or diagnostic agents. The processes according to the present invention can be beneficially applied for the synthesis of various active pharmaceutical ingredients, such as aliskiren or crypthophycin.
Extensive tendon ossification is thought to be rare and is hypothesised to occur due to cell-mediated tissue remodelling. Literature outlining risk factors for the development of an ossified segment, and then a consequent fracture is limited to case reports and case series. A woman in her fifties with a background of several autoimmune disorders presented to a sports and exercise medicine clinic with posterior ankle pain following a bout of brisk walking a month prior. CT and MRI imaging demonstrated a fractured extensively ossified segment of the corresponding Achilles tendon. Conservative treatment was trialled for six months, however, was unsuccessful. Surgical excision of the calcified fragment and flexor hallucis longus tendon transfer were suggested as a potential solution. This case is compared with and builds on current literature surrounding pathophysiology and optimal treatment of extensively ossified segments of the Achilles tendon.
Small cell lung cancer (SCLC) accounts for about 13%~17% of primary bronchial lung cancer. Due to its rapid growth rate, aggressive behavior, early metastasis and poor prognosis, about 70% of patients were diagnosed with extensive-stage (ES) disease. Although most ES-SCLC patients are sensitive to initial chemotherapy, local recurrence and distant metastasis develop in the short term. Immunotherapy has brought the dawn to overcome it. At present, immune checkpoint inhibitor combined with chemotherapy has become an important strategy as first-line therapy for ES-SCLC. Nevertheless, patients are still at a high risk of chest lesion recurrence after initial systemic therapy. Whether the addition of thoracic consolidation radiotherapy (TRT) can reduce chest lesion recurrence rate remains to be determined. In this review, we summarized the latest research progress in the mode of first-line chemotherapy combined with immunotherapy followed by TRT in ES-SCLC, aiming to provide reference for clinical practice.
Participants will receive SD-809 orally twice daily (BID) starting at 12 mg/day, which will be titrated based on dyskinesia control and tolerability up to a maximum total dose of 48 mg/day. Participants who decline to participate in Part B, will continue at their stable dose of SD-809 BID up to Week 158.
Spontaneous bacterial peritonitis (SBP), infection of the peritoneal fluid(ascites) without evidence of a surgically treatable source, is a common and frequently fatal complication of patients with endstage hepatic cirrhosis. It originates with the passage of bacteria from the intestinal lumen to the systemic circulation and then to the ascitic fluid. Early diagnosis with paracentesis (aspiration of an ascites fluid sample to assess for evidence of infection) and the development of nonnephrotoxic third generation cephalosporin antibiotics have decreased the in hospital mortality from nearly 100% to approximately 30%. Mortality in patients with SBP is invariably associated with the development of functional renal failure. Recently, the administration of two large doses of human serum albumin at diagnosis and at 72 hours has been reported to further reduce mortality and renal failure to 10%. These findings have lead to the recommendation that patients with SBP be treated with albumin. However, no study has evaluated the necessary amount and timing of albumin administration required for its beneficial action.

In this study we test the hypothesis that the administration of a second dose of albumin at 48 hours only to patients with renal insufficiency, is as effective at preventing kidney failure as administering the second dose to all patients at 72 hours.

80 consecutive patients with cirrhosis and SBP who are at risk for renal failure will be enrolled at either the Columbia University Medical Center or The New York Hospital Weill Cornell Medical Center. Baseline clinical and biochemical data will be obtained for etiology and severity of liver disease. All patients will receive antibiotics and salt poor albumin at 1.5g/kg at time of diagnosis and diuretics discontinued (current standard of care). Patients will be randomized to receive the second dose (1.0 gm/kg) at 72 hours (group 1, standard of care) or at 48 hours only if renal function remains elevated after two days of therapy (Group 2). For the latter group of patients, albumin will be administered if the Cr is \> 1.0 mg/dl or if the BUN or creatinine levels are higher than admission levels at 48 hours. If albumin is not administered at 48 hours, renal function will be monitored daily, and it will be administered should the BUN or creatinine increase to levels greater than those on admission. Renal failure rates, duration of transient azotemia, mortality, and albumin utilization rated will be compared between the groups who receive albumin in the usual manner at 72 hours versus those who receive it at 48 hours based on renal function.
A metamaterial structure, forming an atomic forcipes, including a topological conductor, a topological insulator abutting the topological conductor, and a gallery between the topological conductor and the topological insulator. The topological conductor has deuterons as chemical adducts. The topological insulator expresses a net negative surface charge and has paramagnetic properties. The gallery has charged intercalated ions. The topological conductor includes deuterated ferromagnetic graphene sheets. The topological insulator can include a clay sheet disposed between the graphene sheets. The atomic forcipes includes a nuclear magnetic isotope disposed in the gallery and formed as an adduct to the clay sheet. The atomic forcipes includes a transceiver, a transmitter, a receiver, a sensor, or an actuator. Included is a body-machine interface where atomic forcipes is disposed in or on a biological structure. The atomic forcipes transceives acoustic signal or electromagnetic signal, corresponding an ionic signal or an electrical signal in the biological structure.
PROBLEM TO BE SOLVED: To obtain a hair tonic having improved effectiveness for prevention of depilation and promotion of hair growth while retaining safety to the scalp by making the hair tonic include granule or powder of tourmaline. SOLUTION: This hair tonic is obtained by formulating a hair tonic as a base (e.g. a hair tonic comprising carpronium chloride, vitamin E, essence of Swertia japonica, etc., as an active ingredient, a hair tonic comprising a germicide such as hinokitiol, etc., and an inflammatory agent such as glycyrrhizin, etc., as active ingredients, a hair cosmetic comprising a vitamin such as vitamin A, biotin, etc., as an active ingredient, etc.), with granule of tourmaline, preferably granule having 2-10 mm diameter or powder of tourmaline, preferably powder having several to scores μm diameter. In use, when the hair tonic as the base is a liquid, the base is sufficiently mixed with the granule or the powder of tourmaline and is applied to the scalp.  In the operation, a voltage occurs on the surface of tourmaline to improve electric characteristics, a water cluster is lessened and the active ingredient of the hair tonic is permeated into the scalp.
Described herein are compositions and methods that confine Cerenkov light to a localized area for targeted treatment and/or imaging of tumor cells. In certain embodiments, such compositions include a Cerenkov-activated tagging agent comprising a payload and a covalent binding unit such as an azide. The payload can be an imaging agent, a contrast agent, and/or a therapeutic. In certain embodiments, a radiolabelled biomarker (e.g.,  18 F-FDG (fluorodeoxyglucose),  18 F-FLT (fluorothymidine)) or other radiolabelled tumor cell targeting agent that emits Cerenkov luminescence is also administered. Upon local illumination by the Cerenkov luminescence at or near the location of the tumor cells, the payload (the imaging agent, contrast agent, and/or therapeutic) is activated. In this way, activation of the imaging agent, contrast agent, and/or therapeutic agent is limited to the region at or near the location of the tumor cells.
BACKGROUND: The increased prevalence of physical diseases among individuals with mental illness contributes to their increased risk of mortality. However, the mediating role of specific diseases in the effect of mental illness on mortality is not well understood.
METHOD: We conducted a longitudinal causal mediation analysis using data from beneficiaries of a South African medical insurance scheme from 2011 to 2020. We estimated the overall effect of major depressive disorder (MDD) on mortality and evaluated reductions in this overall effect through hypothetical interventions on the risks of mediating physical diseases using an interventional effects approach. Monte Carlo simulation-based g-computation was used for estimation.
RESULTS: Among 981,540 individuals, 143,314 (14.6%) were diagnosed with MDD. Mortality risk after 8 years was 6.5% under MDD, and 5.3% under no MDD (risk ratio 1.23, 95% CI = 1.19, 1.26). Overall, 43.4% of this disparity could be attributed to higher rates of physical comorbidities due to MDD. Cardiovascular diseases accounted for 17.8%, followed by chronic respiratory diseases (8.6%), cancers (7.5%), diabetes and chronic kidney disease (5.8%), tuberculosis (4.3%), and HIV (2.7%).
CONCLUSION: Within the privately insured population of South Africa, MDD is associated with increased mortality. We found that noncommunicable diseases, rather than infectious diseases, are important mediators of the effect of MDD on mortality.
Participant who has received his first dose of vaccine and who performs his serological test when he receives the second dose of vaccine against the SARS-CoV-2 virus to determine his immunity. The second serological test will be done 12 to 14 weeks after the second dose of the SARS-CoV-2 vaccine to determine its immunity.
Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin releasing hormone (GnRH or LH-RH). The analog possesses greater potency than the natural hormone. The chemical name is 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide acetate (salt) with the following structural formula:

  


  


Leuprolide acetate injection is a sterile, aqueous solution intended for subcutaneous injection. It is available in a 2.8 mL multiple-dose vial containing leuprolide acetate, USP (5 mg/mL), sodium chloride, USP (6.3 mg/mL) for tonicity adjustment, benzyl alcohol, NF as a preservative (9 mg/mL), and water for injection, USP. The pH may have been adjusted with sodium hydroxide, NF and/or glacial acetic acid, USP. The pH range is 4.5 to 6.5.